Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Comments

Post a Comment

Popular posts from this blog

IPL 2022: Maximum of 4 players can be retained, new teams can pick 3 players before mega auction

IPL 2022: The BCCI, in a letter to the franchises, confirmed that the existing 8 teams will be allowed to retain a maximum of 4 players between November 1 and November 25. The two new teams can pick a maximum of 3 players before the mega auction. BCCI confirms IPL 2022 retention rules in a letter to franchises (Courtesy of BCCI) HIGHLIGHTSA maximum of 4 players can be retained by exisiting franchises before mega auctionExisiting teams can retain players between November 1 and 30New teams allowed to pick maximum of 3 players before auction Indian Premier League teams can retain up to 4 players in the lead up to the mega auction for IPL 2022, the Board of Control for Cricket in India (BCCI) has conveyed in a letter to the franchises. The two new teams who will be part of the next season will be allowed to pick 3 players before the auction. A source close to the board confirmed the developments to India Today on Saturday. The existing 8 franchises will be allowed to retain their players b...
Read more

Moderna testing 2 booster shots to protect against Omicron variant, expects data soon

US-based pharmaceutical giant Moderna is studying two booster shot options designed to anticipate mutations similar to the Omicron strain of the coronavirus, which has been designated as a variant of concern by the WHO. It is already working to test the ability of the current vaccine dose to neutralise the Omicron variant and data is expected in the coming weeks. “Moderna is already studying two multi-valent booster candidates in the clinic that were designed to anticipate mutations such as those that have emerged in the Omicron variant,” the company said in a statement. The first candidate (mRNA-1273.211) includes several mutations present in the Omicron variant that were also present in the Beta variant of concern1. Moderna said it has completed dosing in a potentially pivotal safety and immunogenicity study of mRNA-1273.211 at the 50 µg (N=300) and 100 µg (N=584) dose levels. ALSO READ | PM Modi chairs key meet on Covid-19, vaccination status amid concerns over Omicron variant A sec...
Read more